Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Shanghai Junshi Biosciences Co., Ltd. (688180.SS)
Shanghai, CN
Shanghai Junshi Biosciences Co., Ltd. is a biopharmaceutical enterprise dedicated to the research, development, and marketing of innovative therapeutic agents. Operating within the People's Republic of China, their focus spans critical medical areas such as oncology, metabolic diseases, autoimmune disorders, neurological conditions, and infectious diseases. Among its principal offerings is JS001, commercialized as TUOYI. This recombinant humanized anti-PD-1 monoclonal antibody has received approval for a broad spectrum of cancer indications, including various forms of melanoma, soft tissue sarcoma, nasopharyngeal carcinoma, urothelial carcinoma, non-small cell lung carcinoma, triple-negative breast carcinoma, esophageal squamous cell carcinoma, and hepatocellular carcinoma. Beyond TUOYI, Junshi Biosciences boasts a robust pipeline of investigational drugs. These include UBP1211, a biosimilar of Humira, targeting conditions like rheumatoid arthritis, ankylosing spondylitis, and psoriasis; JS002, a recombinant humanized anti-PCSK9 monoclonal antibody aimed at hyperlipidemia; and UBP1213, a recombinant humanized anti-BLyS monoclonal antibody in injectable form. Further developments encompass JS501, a biosimilar to Avastin; JS003, a recombinant humanized anti-PD-L1 monoclonal antibody for injection; JS101, identified as a pan-CDK inhibitor; TAB004/JS004, a recombinant humanized anti-BTLA monoclonal antibody; and JS005, a recombinant humanized anti-IL-17A monoclonal antibody for injection. The company has also established strategic collaborations. Notably, it partners with Eli Lilly and Company on the co-development of therapeutic antibodies intended for the prevention and treatment of COVID-19, the illness caused by the SARS-CoV-2 novel coronavirus. Additionally, an alliance with Coherus Biosciences, Inc. facilitates the development and commercialization of toripalimab, Junshi Biosciences' anti-PD-1 antibody. Founded in 2012, Shanghai Junshi Biosciences Co., Ltd. maintains its corporate headquarters in Shanghai, People's Republic of China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.18% | -6.98% | -15.21% | +0.71% | -7.71% | +0.23% | +5.32% | -26.19% | -61.96% | -77.32% | -77.32% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+28.2% ★ Q1'26: +45.1% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+33.1% ★ Q1'26: +91.7% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-43.5% Q1'26: -26.4% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-40.9% Q1'26: -15.3% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-14.6% ★ Q1'26: -5.9% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+2.0% ★ Q1'26: +4.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-5.44× Q1'26: -13.43× (vs Q1'25)
| Metric |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 4 Rev. Ana. 2 EPS Ana. |
Dec 2027 4 Rev. Ana. 2 EPS Ana. |
Dec 2028 2 Rev. Ana. 3 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
934.0K
est: 1.00M (-6.6%)
|
775.09M
est: 1.05B (-26.5%)
|
1.59B
est: 1.53B (+4.1%)
|
4.02B
est: 3.69B (+9.0%)
|
1.45B
est: 1.73B (-16.1%)
|
1.50B
est: 1.60B (-6.1%)
|
1.95B
est: 1.82B (+6.9%)
|
2.50B
est: 2.54B (-1.5%)
|
3.34B
3.29B – 3.42B
+31.6% YoY
|
4.12B
4.03B – 4.30B
+23.5% YoY
|
4.88B
4.82B – 5.00B
+18.4% YoY
|
| EBITDA |
-683.56M
est: -733.6K (-93,079.8%)
|
-709.29M
est: -773.77M (+8.3%)
|
-1.52B
est: -1.12B (-35.6%)
|
-363.43M
est: -2.71B (+86.6%)
|
-2.40B
est: -1.27B (-89.0%)
|
-2.19B
est: -1.17B (-86.6%)
|
-1.05B
est: -1.07B (+2.1%)
|
-762.06M
est: -1.49B (+48.8%)
|
-1.96B
-2.00B – -1.93B
-31.6% YoY
|
-2.42B
-2.52B – -2.36B
-23.5% YoY
|
-2.86B
-2.93B – -2.83B
-18.4% YoY
|
| EBIT |
-713.49M
est: -773.1K (-92,193.0%)
|
-753.32M
est: -815.41M (+7.6%)
|
-1.64B
est: -1.18B (-38.7%)
|
-573.17M
est: -2.86B (+79.9%)
|
-2.65B
est: -1.34B (-97.4%)
|
-2.46B
est: -1.24B (-99.1%)
|
-1.31B
est: -1.17B (-11.3%)
|
-1.02B
est: -1.63B (+37.5%)
|
-2.15B
-2.20B – -2.12B
-31.6% YoY
|
-2.66B
-2.77B – -2.59B
-23.5% YoY
|
-3.14B
-3.22B – -3.10B
-18.4% YoY
|
| Net Income |
-716.41M
est: -673.12M (-6.4%)
|
-747.42M
est: -641.97M (-16.4%)
|
-1.67B
est: -1.32B (-26.0%)
|
-720.91M
est: -464.83M (-55.1%)
|
-2.39B
est: -2.21B (-8.1%)
|
-2.28B
est: -1.93B (-18.1%)
|
-1.28B
est: -1.17B (-9.9%)
|
-875.17M
est: -831.67M (-5.2%)
|
-402.56M
-415.30M – -395.97M
+51.6% YoY
|
62.98M
61.95M – 64.97M
+115.6% YoY
|
361.53M
355.62M – 372.98M
+474.0% YoY
|
| SGA |
145.14M
est: 726.4K (+19,879.7%)
|
536.98M
est: 766.22M (-29.9%)
|
1.13B
est: 1.11B (+1.3%)
|
1.38B
est: 2.68B (-48.7%)
|
1.29B
est: 1.26B (+2.8%)
|
1.38B
est: 1.16B (+18.8%)
|
1.51B
est: 1.29B (+16.8%)
|
1.54B
est: 1.80B (-14.1%)
|
2.36B
2.33B – 2.42B
+31.6% YoY
|
2.92B
2.85B – 3.05B
+23.5% YoY
|
3.46B
3.41B – 3.54B
+18.4% YoY
|
| EPS |
-1.19
est: -0.68 (-74.1%)
|
-0.96
est: -0.65 (-47.3%)
|
-2.03
est: -1.34 (-51.0%)
|
-0.81
est: -0.47 (-71.6%)
|
-2.60
est: -2.24 (-16.0%)
|
-2.32
est: -1.96 (-18.1%)
|
-1.30
est: -1.16 (-12.1%)
|
-0.87
est: -0.83 (-5.1%)
|
-0.40
-0.41 – -0.39
+51.6% YoY
|
0.06
0.06 – 0.06
+115.6% YoY
|
0.36
0.35 – 0.37
+474.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-25 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Global X China Biotech ETF (HKD) 2820.HK | 1.81% | 1.45M | 0.68% |
| 2 | Xtrackers Harvest CSI 500 China A-Shares Small Cap ETF ASHS | 0.19% | 69.9K | 0.65% |
| 3 | Xtrackers Harvest CSI A500 UCITS ETF 1D AH50.L | 0.06% | 9.8K | 0.65% |
| 4 | KraneShares ICBCCS S&P China 500 Index UCITS ETF CHIN.L | 0.05% | 39.1K | 0.55% |
| 5 | Xtrackers Emerging Markets Carbon Reduction and Climate Improvers ETF EMCR | 0.02% | 11.3K | 0.15% |
| 6 | Goldman Sachs MarketBeta Total International Equity ETF GXUS | 0.01% | 69.3K | 0.18% |
| 7 | Franklin FTSE China ETF FLCH | 0.01% | 27.2K | 0.19% |
| 8 | Franklin FTSE China UCITS ETF FLXC.L | 0.01% | 157.1K | 0.19% |
| 9 | Schwab Emerging Markets Equity ETF SCHE | 0.00% | 419.9K | 0.06% |
| 10 | Vanguard FTSE Emerging Markets UCITS ETF (USD) Distributing VDEM.L | 0.00% | 151.9K | 0.17% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jianjun Zou | GM, Chief Executive Officer & Executive Director | 10M | — |
| Gang Wang | Executive Director, Chief Quality Officer & Senior Vice President of Industry Affairs | 5M | male |
| Jun Xiong | Executive Chairman | 4M | male |
| Ning Li | Executive Vice-Chairman of the Board | 4M | — |
| Zhuobing Zhang | Deputy GM & Executive Director | 4M | male |
| Sheng Yao | Deputy GM, Senior Vice President & Executive Director | 3M | — |
| Xin Li | Senior Vice President of Government Affairs & Executive Director | 2M | — |
| Cong Li | Co-CEO & Executive Director | 2M | male |
| Zhengyu Wang | Joint Company Secretary | — | male |
| Baohong Xu | Chief Financial Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 688180.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
